Supporting patients living with chronic non-cancer pain – the role of the pharmacist
Join our panel of chronic pain experts as they discuss evidence-based approaches for managing chronic non-cancer pain and the role of pharmacists in reducing opioid-related harms.
This webinar has been developed with funding from the Therapeutic Goods Administration, Australian Government Department of Health.
Thursday, 17 September 2020
7:00 – 8:00 pm AEST
Registrations for this webinar are now closed.
An on-demand recording will be made available shortly.
New asthma guidelines: what’s changed?
Join our panel of experts as they discuss the recent changes to asthma guidelines and what this means in practice.
Tuesday, 29 September 2020
7:00 – 8:00 pm AEST
Working together to enhance transitions of care for people with dementia
Using real-life case scenarios, the panel, consisting of a geriatrician, GP and nurse, will discuss the challenges of optimising transitions of care for people living with dementia.
This webinar has been developed in partnership with Dementia Training Australia.
Listen to our interdisciplinary panel discuss the challenges of optimising transitions of care for people living with dementia.
Opioids: reducing harms from long-term use
Discuss benefits and harms of opioids with patients and explore non-pharmacological alternatives.
PPIs in GORD: supporting patients to step down
Discuss your patients' expectations of gastro-oesophageal reflux disease (GORD) management and assess their ongoing need for Proton-pump inhibitors (PPIs) with the aim of stepping down treatment.
Type 2 diabetes: a patient-centred approach
Update your knowledge about the range of glucose-lowering medicines available and their role in the treatment of type 2 diabetes.
Statins: promoting adherence, addressing intolerance
Optimise your patients’ adherence to lipid-modifying medicines and improve your confidence in assessing suspected statin-associated muscle symptoms.
PPIs: reviewing treatment for gastro-oesophageal reflux disease
How would you advise a patient with well-controlled gastro-oesophageal reflux disease (GORD) who would like to continue their proton pump inhibitor (PPI) therapy?